pectoral nerve block in breast cancer surgery
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: - Health Condition 2: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2021/05/033304
- Lead Sponsor
- JLN Medical College Ajmer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Both sex
ASA class I and II
Patients undergoing elective surgeries under general anaesthesia
Exclusion Criteria
Patient refusal
Patient with known drug allergy
Deranged coagulation profile
Pregnancy
Severe cardiac/pulmonary/neurological diseases
BMI >35
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the analgesic effects of dexamethasone in Pecs block for breast cancer surgery?
How does 0.25% Ropivacaine compare to standard-of-care analgesics in postoperative breast cancer patients?
Are there specific biomarkers that predict enhanced analgesic response to Ropivacaine-dexamethasone combinations in breast cancer surgery?
What are the potential adverse events associated with Pecs block using Ropivacaine and dexamethasone in breast cancer patients?
How do combination approaches of local anesthetics and corticosteroids influence postoperative outcomes in C509 breast cancer cases?